PNC Financial Services Group Inc. Grows Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 90.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,203 shares of the company’s stock after buying an additional 1,992 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Amphastar Pharmaceuticals were worth $156,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of AMPH. Pacer Advisors Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp increased its stake in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after purchasing an additional 439,281 shares during the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new position in Amphastar Pharmaceuticals during the third quarter worth about $10,804,000. Portolan Capital Management LLC boosted its stake in Amphastar Pharmaceuticals by 201.1% in the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock worth $15,906,000 after buying an additional 218,901 shares during the last quarter. Finally, Weiss Asset Management LP purchased a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at about $4,967,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ AMPH opened at $28.29 on Monday. The stock has a market capitalization of $1.35 billion, a PE ratio of 9.43, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a fifty day moving average of $31.91 and a 200-day moving average of $40.48. Amphastar Pharmaceuticals, Inc. has a 52-week low of $25.89 and a 52-week high of $53.96.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.